Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In the Original Investigation entitled “Cannabinoids for Medical Use: A Systematic Review and Meta-analysis,” published in the June 23/30, 2015, issue of JAMA,1 incorrect wording for an effect estimate was reported in the fifth sentence of the Sleep Disorder section. The sentence should read as follows: “This suggested that nabilone was associated with improvements in insomnia (mean difference from baseline, −3.25 [95% CI, −5.26 to −1.24]) and with greater sleep restfulness (mean difference from baseline, 0.48 [95% CI, 0.01 to 0.95]).” This change does not affect the results of the investigation. This article was corrected online. This article was also corrected on June 26, 2015, for incorrect axis labeling (Figure 4)2; on July 13, 2015, for a corrected average reduction to the Ashworth spasticity scale (as reported in the Abstract)3; and on November 5, 2015, for an incorrect nonproprietary name and approved use for a drug in Table 1.4
Incorrect Effect Estimate. JAMA. 2016;315(14):1522. doi:10.1001/jama.2016.3470